A Leading HIV Drug Is Way Overpriced in the U.S.

(Bloomberg Opinion) -- Gilead Sciences Inc. CEO Daniel O'Day has only been on the job since March, and he's already found himself having to defend his company in front of  the House Oversight and R...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.